Virology Testing Market Report Scope & Overview:

The Virology Testing Market size is valued at USD 7.05 Billion in 2025 and is projected to reach USD 15.20 Billion by 2035, growing at a CAGR of 8.07% during the forecast period 2026–2035.

The Virology Testing Market study report offers a thorough review of market trends, technologies, and diagnosis. Market growth is expected to be fueled by increased cases of infectious diseases, rising requirements for molecular diagnosis, high uptake of NGS and CRISPR tests, and improved healthcare facilities from 2026 to 2035.

In 2025, the number of virology tests conducted exceeded 3.54 billion tests, owing to PCR test usage, serological tests for HIV and hepatitis, and the need for diagnosis of respiratory diseases, including influenza and COVID-19.

Market Size and Forecast:

• Market Size in 2025: USD 7.05 Billion

• Market Size by 2035: USD 15.20 Billion

• CAGR: 8.07% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

To Get More Information On Virology Testing Market - Request Free Sample Report

Virology Testing Market Trends:

• The uptake of next-generation sequencing (NGS) is increasing for genomic surveillance and detection of variants.

• CRISPR-based rapid diagnostic tests are set to disrupt the diagnostic market with point-of-care application.

• Test decentralization is increasing in terms of at-home use and point-of-care testing post-COVID.

• Automation and incorporation of AI is revolutionizing the accuracy and efficiency of virology test methods.

• Increased demand for vaccine research from pharmaceutical and biotech companies.

• Bioinformatics platforms are gaining traction due to data processing problems from NGS.

• Cooperation between organizations (WHO, CDC, Regional Health Organizations) on viral surveillance.

• Slow approval rates due to regulations are still an obstacle, especially in North America and Europe.

• Funding constraints are limiting the adoption of advanced technologies in underdeveloped regions.

• Hospital laboratories and diagnostic laboratories are the biggest consumers of the market; however, there is growth in specialty clinics and research organizations.

U.S. Virology Testing Market Insights:

The U.S. Virology Testing Market is projected to grow from USD 2.32 Billion in 2025 to USD 4.87 Billion by 2035, at a CAGR of 8.60%. The growth factors include the increasing prevalence of infectious diseases, growing requirements for fast diagnostic tests, robust adoption of advanced molecular techniques such as PCR, NGS, and CRISPR testing, and significant funding for new technologies in PoC, home use, and central laboratories.

Virology Testing Market Growth Drivers:

• Rising infectious disease prevalence and emerging viral outbreaks are driving demand for advanced virology testing solutions.

Growing incidences of HIV, hepatitis, influenza, and COVID-19 and potential outbreaks of viruses such as Zika, Ebola, and Nipah play an important role in propelling the virology testing market. Growing implementation of sophisticated technologies for the diagnosis of infections caused by viruses is witnessed in hospitals, diagnostic laboratories, and home care health organizations in the form of PCR tests, NGS tests, CRISPR tests, and rapid tests due to their enhanced efficacy and accuracy.

More than 48% of hospitals, diagnostic laboratories, and home health care companies have adopted advanced virology testing in 2025 to detect viruses.

Virology Testing Market Restraints:

• High equipment costs and regulatory hurdles are restraining broader adoption of advanced virology testing solutions.

The high costs involved in PCR equipment, NGS technology, and CRISPR diagnostics hinder access in developing countries due to reagents and consumables. Hospitals, diagnostic centers, and home care agencies may not have enough budgets for incorporating modern equipment. Moreover, the process of receiving approvals from health authorities such as the Food and Drug Administration in the U.S. and European Medicines Agency in Europe takes time. Data management, lack of competent personnel, and disparity in health facilities prevent widespread adoption.

Over 42% of healthcare organizations mentioned costs and regulations in 2025 as impediments to expanding virology testing services.

Virology Testing Market Opportunities:

• Growing development of advanced molecular diagnostics and personalized virology testing presents significant market expansion opportunities.

Emerging developments in PCR tests, next-generation sequencing, CRISPR-based assays, and multiplex diagnostics create many promising opportunities for the testing market in virology. There is a growing trend toward utilizing such technologies in the hospitals, diagnostic labs, and home healthcare facilities for the better detection, monitoring, and management of infectious diseases. It will provide great possibilities for pharmaceutical and biotech companies that offer innovative testing kits and devices that are safe and user-friendly. Development of POC devices, home-based tests, and genomic surveillance using bioinformatics creates a solid basis for the expansion of the market.

In 2025, more than 56% of health institutions implemented innovative tests and solutions for virology testing.

Virology Testing Market Segmentation Analysis:

• By Application, Infectious Disease Diagnosis dominated with 54.61% market share in 2025, whereas Research & Development are projected to record the fastest CAGR of 9.57% through 2026–2035.

• By Test Type, Polymerase Chain Reaction (PCR) held the largest market share of 41.89% in 2025, while CRISPR-based Testing (emerging subsegment) are expected to grow at the fastest CAGR of 10.34% during 2026–2035.

• By Product, Reagents accounted for the highest market share of 29.47% in 2025, while Consumables & Assay Kits are expected to grow at the fastest CAGR of 9.28% during the forecast period.

• By End User, Hospitals & Clinics dominated with a 34.74% share in 2025, while Home-Based Testing are anticipated to expand at the fastest CAGR of 10.47% through 2026–2035.

• By Testing Methodology, Molecular Diagnostics (PCR, NGS, CRISPR) held the largest share of 49.49% in 2025, while Decentralized/POC Testing are expected to grow at the fastest CAGR of 10.87% during the forecast period.

By Application, Infectious Disease Diagnosis dominates while Research & Development emerges as the fastest-growing subsegment:

Infectious Disease Diagnosis will remain a dominant force in the virology testing market owing to the important part that it plays in diagnosing viral diseases including HIV, hepatitis, influenza, and COVID-19 infections that are prevalent. Health care organizations depend greatly on infectious disease diagnosis to be able to treat patients efficiently.

Research and development will experience fastest growing as pharmaceutical and biotechnology firms continue investing in finding antiviral drugs and vaccines. Biotechnology firms will make use of innovative techniques in molecular diagnostics to develop better diagnostic methods in order to provide better treatment for viral diseases.

By Test Type, Polymerase Chain Reaction (PCR) dominates while CRISPR-based Testing emerges as the fastest-growing subsegment:

PCR is likely to remain the dominant technology within the virology testing market on account of its reliable and accurate nature and extensive use in the field. Being considered the gold standard of viral diagnosis, PCR enjoys a high level of favor among health care professionals when it comes to diagnosing and monitoring patients.

CRISPR-based Testing represents the most fastest frowing category of technologies within the virology testing market. This trend is largely associated with CRISPR's ability to provide quick results and offer patient-specific solutions for diagnosing various viruses.

By Product, Reagents dominate while Consumables & Assay Kits emerge as the fastest-growing subsegment:

Reagents remain the most dominant product in the virology testing industry due to they are key components in PCR-based, serological, and molecular diagnostics testing. The repetitive consumption of reagents by hospitals, diagnostic labs, and research institutes results in high preferences from end users.

Consumables and assay kits have emerged as the fastest growing product segments due to an increasing requirement for easy-to-use diagnostic tools. Consumables and kit-based testing systems are becoming more popular in-home healthcare facilities, POC centers, and decentralized testing labs.

By End User, Hospitals & Clinics dominate while Home-Based Testing emerges as the fastest-growing subsegment:

The Hospitals & Clinics segment holds the dominant position in the virology testing industry owing to its importance in managing infectious diseases, routine diagnostic tests, and critical care services. Its extensive facilities, availability of sophisticated equipment, and dependence on PCR-based and serological tests contribute to high adoption levels.

The Home-Based Testing sub-segment represents the fastest growing component in the industry, fueled by the increasing requirement for user-friendly and fast diagnostic testing solutions. Adoption rates are increasing as more patients and medical professionals leverage point-of-care kits to increase outreach and enhance early disease detection.

By Testing Methodology, Molecular Diagnostics dominate while Decentralized/POC Testing emerges as the fastest-growing subsegment:

Molecular Diagnostics segment continue to hold dominant position in the market, which include PCR, NGS, and CRISPR-based diagnostics, for virology tests due to their exceptional precision and sensitivity and their capability to identify many kinds of viruses. Their high rates of adoption among hospitals, diagnostic centers, and research institutes attest to their status as the benchmark for viral diagnosis and genome tracking.

Decentralized/POC Testing is expected to witness the fastest growth rate among all the subsegments within the industry. The increasing need for quick, convenient, and patient-friendly diagnostic methods has spurred the use of mobile kits and point-of-care instruments.

Virology Testing Market Regional Analysis:

North America Virology Testing Market Insights:

The North American virology testing market is a dominating in the market at 37.68% share, due to its highly developed healthcare system, highly skilled clinicians, and extensive use of molecular diagnostics. The hospitals and diagnostic centers in the United States and Canada are largely dependent on PCR and serological testing for the management of infections, although next-generation sequencing and CRISPR are increasingly being used for research purposes. North America's leading position in the market is further consolidated by the presence of favorable reimbursement policies, government initiatives, and innovative technologies in POCT and home tests.

Get Customized Report as Per Your Business Requirement - Enquiry Now

U.S. Virology Testing Market Insights:

The United States represents a dominant force within the North American market of virology tests owing to well-established healthcare facilities, high number of tests performed, and high usage of molecular diagnostics. High levels of consumption of PCR tests, next-generation sequencing, and multiplex panels are seen in hospitals, specialist centers, and research laboratories due to their accuracy in diagnosing and monitoring viral infections. Increasing funding in genomics, active development pipeline in biotech companies, and positive reimbursements policies ensure steady growth. The United States is the biggest contributor to the virology test market.

Asia-Pacific Virology Testing Market Insights:

Asia-Pacific market growth is rapidly increasing with CAGR of 9.41% on account of increased prevalence of infectious diseases, higher investments made in the health care sector, and increased acceptance of molecular diagnostic technologies. Nations in this region have been working on improving their programs for monitoring viruses, and have increased the use of PCR, NGS, and POC testing methods. The increasing number of hospitals and laboratories that diagnose diseases, and governmental and private sector initiatives, are leading factors fueling this market’s rapid growth rate.

China Virology Testing Market Insights:

The Chinese virology test market is spurred on by widespread screening initiatives for infectious diseases, strong governmental backing, and the fast embrace of cutting-edge diagnostic technology. Chinese hospitals and laboratories are adopting more PCR tests, next-generation sequencing tests, and CRISPR tests for managing viruses. The increasing drug research and development pipeline and investment into point-of-care and at-home tests fuel further market expansion. In addition, China’s focus on innovation, cost-effectiveness, and accessibility places it well to become an important factor behind Asia-Pacific’s dominance of the world virology test market.

Europe Virology Testing Market Insights:

The European market for virology testing enjoys the advantage of having efficient healthcare systems, robust regulations, and extensive use of modern technology. German, French, and British hospitals and labs have a preference for using PCR and serology tests for treating infections. There is a rising need for NGS and multiplex tests that encourage technological advancement, coupled with public-funded schemes that enhance virus surveillance. The pharmaceutical and biotechnology industries are focusing on research and development, extending uses for vaccine and genomics applications.

Germany Virology Testing Market Insights:

Germany has a leading position in the European market for virology testing due to its excellent healthcare facilities, robust laboratory systems, and extensive use of molecular tests. The demand for PCR, NGS, and multiplex testing comes mainly from hospitals and research organizations, where the accuracy of viral infection diagnosis is guaranteed. Efforts by the government to improve the system of infectious disease monitoring, along with drug research and development, further boost the growth of the market.

Latin America Virology Testing Market Insights:

The Latin American market for virology testing is growing due to high levels of infectious diseases, increased health spending, and the widespread use of point-of-care diagnostic tests. Many countries including Brazil and Mexico are developing their virus surveillance systems, making more PCR and serology tests available. Infrastructure limitations and costs continue to pose barriers to entry, but the situation is being improved through government efforts and private partnerships. Increased drug development activity and a heightened focus on early diagnosis are fueling demand.

Middle East & Africa Virology Testing Market Insights:

The Middle East & Africa market is showing steady growth driven by increasing incidences of infections and improvement in healthcare infrastructure and diagnostic advancements. Hospitals and laboratories are using more PCR and serological tests, and POC tests have made access easier in under-served areas. Increased efforts from governments and collaborations ensure that there is effective monitoring and outbreak response. Although there are issues related to affordability and poor infrastructure, investment and early detection awareness have been boosting the uptake of testing in this market.

Virology Testing Market Competitive Landscape:

Roche Diagnostics

Roche Diagnostics is among the top providers of molecular diagnostic tools on an international scale, with its extensive contribution to the field of virology testing services, which is evident from its range of PCR-based technologies, including the cobas family of tests, predominantly utilized for the identification of HIV, hepatitis viruses, and respiratory viruses. Roche’s focus on precision, scalability, and automation is further complemented by rigorous clinical trials and efficient logistics.

• In August 2025, Roche expanded its cobas 6800/8800 systems with multiplex assays for simultaneous detection of influenza, RSV, and SARS-CoV-2, enhancing laboratory efficiency and viral surveillance capacity.

Abbott Laboratories

Abbott is one of the prominent health care firms in the United States that enjoys a high reputation in the area of virology testing due to m2000 RealTime and Alinity™ platforms for PCR diagnosis. The company offers a wide array of tests for HIV, hepatitis, and novel viruses. Emphasis is put on the quality and convenience of the tests offered. Abbott’s commitment to point-of-care tests and the ID NOW™ molecular platform, in particular, demonstrates the company’s dedication to decentralizing and providing convenient testing services.

• In December 2025, Abbott advanced its ID NOW platform with enhanced respiratory virus panels, strengthening its leadership in rapid point-of-care diagnostics.

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is one of the leading companies in the world of biotechnology and diagnostics. It is known for its robust presence in the field of virology testing by providing PCR instruments under the brand name Applied Biosystems™ and Ion Torrent™ next-generation sequencing systems, among many other reagents and consumables. Thermo Fisher Scientific focuses on innovations in molecular diagnostics, genomic surveillance, and bioinformatics.

• In June 2025, Thermo Fisher expanded its Ion Torrent™ Genexus System applications for viral genome sequencing, supporting rapid identification of variants and strengthening surveillance programs.

Virology Testing Market Key Players:

Some of the Virology Testing Market Companies are: 

• Roche Diagnostics

• Abbott Laboratories

• Thermo Fisher Scientific

• Qiagen

• Bio-Rad Laboratories

• Siemens Healthineers

• Danaher Corporation (Cepheid)

• Becton Dickinson (BD)

• Hologic Inc.

• PerkinElmer Inc.

• Agilent Technologies

• Illumina Inc.

• Merck KGaA

• bioMérieux SA

• GenScript Biotech

• Luminex Corporation

• Sysmex Corporation

• Randox Laboratories

• Myriad Genetics

• OraSure Technologies